Paratek clears one last big hurdle on the way to an FDA marketing decision for antibiotic
Paratek’s $PRTK antibiotic omadacycline went three for three in Phase III. And now it looks ready to move on to a near-term FDA approval. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
